What Is Jyong Biotech Ltd. (MENS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Jyong Biotech Ltd.'s intrinsic value is estimated at $1.46, suggesting the stock is overvalued at its current price of $2.29. With 7 out of 9 models flagging downside (-36.1% average return), the market may be pricing in unsustainable growth. Notably, First Chicago sees the most upside at +31.7% (fair value: $3.02), while RCMH-DCF is the most conservative at -92.8% ($0.17). The spread between these extremes — +124.4% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About MENS?
9 of 13 models are currently active for MENS. Of these, 2 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates MENS's intrinsic value at $0.41, implying -82.0% downside from the current price. See which stocks rank higher →
How Does MENS Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, MENS ranks #396 by Quality of Company score. CirclFi's QOC score of 2.5/10 evaluates 32 fundamental signals. A score of 2.5 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Jyong Biotech Ltd. competes in an environment where clinical trial success rate often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is MENS a Value Trap?
The Value Trap algorithm is not active for MENS. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Jyong Biotech Ltd.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Jyong Biotech Ltd. is rated at 2.5/10. This weak-tier score exhibits fundamental weaknesses that warrant careful scrutiny.
The gap between the most bullish and bearish model spans +124.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every MENS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across MENS's 9 active models, average confidence is 8%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad